Year |
Citation |
Score |
2016 |
Maurer MJ, Spear ED, Yu AT, Lee EJ, Shahzad S, Michaelis S. Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast. G3 (Bethesda, Md.). PMID 27172186 DOI: 10.1534/G3.116.027953 |
0.543 |
|
2011 |
Thompson CA, Maurer MJ, Allmer C, Slager SL, Yost KJ, Macon WR, Ansell SM, Inwards DJ, Habermann TM, Link BK, Cerhan JR. Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8059. PMID 28023542 DOI: 10.1200/Jco.2011.29.15_Suppl.8059 |
0.321 |
|
2009 |
Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE. Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8508. PMID 27960859 DOI: 10.1200/Jco.2009.27.15_Suppl.8508 |
0.347 |
|
2008 |
Metzger MB, Maurer MJ, Dancy BM, Michaelis S. Degradation of a cytosolic protein requires endoplasmic reticulum-associated degradation machinery. The Journal of Biological Chemistry. 283: 32302-16. PMID 18812321 DOI: 10.1074/Jbc.M806424200 |
0.603 |
|
2008 |
Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore DF, Kurtin P, Witzig TE. A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Journal of Clinical Oncology. 26: 8500-8500. DOI: 10.1200/Jco.2008.26.15_Suppl.8500 |
0.361 |
|
2007 |
Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF, Zwiebel JA, Buckner JC. N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. 25: 2004-2004. DOI: 10.1200/Jco.2007.25.18_Suppl.2004 |
0.32 |
|
2005 |
Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5294-304. PMID 15998902 DOI: 10.1200/Jco.2005.23.622 |
0.344 |
|
2005 |
Galanis E, Buckner JC, Maurer MJ, Hidalgo M, Kreisberg JI, Peralba J, Jenkins RB, Walsh DJ. N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis Journal of Clinical Oncology. 23: 1505-1505. DOI: 10.1200/Jco.2005.23.16_Suppl.1505 |
0.313 |
|
2004 |
Micallef IN, Kahl BS, Gayko U, Cesano A, Ansell SM, Geyer S, Inwards DJ, Maurer MJ, Horning S, Habermann TM. Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) Journal of Clinical Oncology. 22: 6580-6580. DOI: 10.1200/Jco.2004.22.90140.6580 |
0.346 |
|
Show low-probability matches. |